Phase 2, Phase 3RecruitingPriority 3 · Moderate priorityNCT07389616
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Plain-language summary
This Phase 2, Phase 3 trial is testing Cidabenamine and Azacitidine for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Cidabenamine, Azacitidine (DRUG): In the study, Cidabenamine combined with Azacitidine are used as maintenance therapy following allogeneic peripheral blood hematopoietic stem cell transplantation in patients with high-risk peripheral T-cell lymphoma.
- Drugs / treatments
- Cidabenamine, Azacitidine
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details